Nightingale Health - New Blood on the Stock Market

This information from Bloomberg was so interesting that I had to check the fine print.
It states that the offering will not be executed unless at least EUR 60 million is raised. Anchor investors promised EUR 39 million.

Perhaps that EUR 60 million would be at least the Base deal size, if not the EUR 110 million.

p.1


p.41

So, that 110 million is the size of the entire IPO without the additional share tranche. The additional share tranche in an oversubscription situation is a maximum of 27.5 million euros. So, the basic part is already fully subscribed, and at least a portion of the additional share tranche on top of that. At least that’s how I understand it from Mäkinen’s tweet, that according to Bloomberg, subscriptions have now exceeded 110MEUR+.

This offering will easily go through based solely on Bloomberg’s information. And then on the forums after opening day, people will wonder about NH’s stock price, saying it rose incorrectly and why didn’t I understand what kind of company interests the world. It’s probably safe to participate in this, especially with Swedbank’s support in the background.

6 Likes

Normally, the lead manager of an offering has 30 days to, but no obligation to, stabilize the price level to one that would not otherwise prevail in open trading. The lead manager’s fee can be significant, here apparently €8M at that €60M offering level.

This doesn’t quite apply to this topic, but I’m often interested in companies that receive a lot of criticism. I don’t mean that the criticism is unwarranted, and indeed, abundant and diverse critiques do tell you something. I have tried to find out more about the company and understand its potential, I don’t know what my attitude would be if it were constantly praised on this forum. :smiley: Currently, I’m quite critical of this, but that Bloomberg article did make me think a little. :blush:

if it’s impractical technology, no licenses, and the healthcare sector has historically shown no interest despite the technology in question existing for decades, then… I think one can draw conclusions.

Thanks, good blog post, I totally agree.

As Nightingale expands, it will have to collect databases (biobank data) from different regions (countries/continents) from which it can provide customers with answers about their health risks. It just occurred to me what happens to this huge amount of data when the company goes bankrupt? Do the initial investors have ownership rights to this data when the company’s operations cease?

Nothing will be left for shareholders. Maybe something for creditors.

1 Like

I don’t know if it was mentioned, but someone was wondering how customers would find this service. I think Aava adopted the service already in 2019 or 2020. It’s strange that no one seems to have mentioned anything about it.

1 Like

“Bloomberg: Nightingale Has Raised Its Target of 110 Million Euros | Arvopaperi”

4 Likes

It remains to be seen how many people are in it for a quick buck. I’d venture a guess that it’s a large number. In the best-case scenario (from my perspective), the first few days lead to panic and people selling their shares at a loss.
So, I’m not participating in the offering, but I’ll be lurking, ready with my buy trigger if the scenario mentioned above happens.
It could also go up if the average Joes still have some money left after the offering.

1 Like

Old news, but very interesting from the perspective of future possibilities.
https://thl.fi/fi/web/thl-biopankki/-/nightingale-ja-thl-biopankki-edistavat-yksilollista-terveydenhoitoa-analysoiden-40-000-naytetta
https://www.biopankki.fi/

A slightly Oura-type biohacking approach is very welcome in this business as well.
https://www.businessfinland.fi/ajankohtaista/uutiset/2017/fazer-nokia-ja-nightingale-health-yhteistyohon-paremman-ravitsemuksen-ja-terveyden-edistamiseksi
https://www.fazergroup.com/globalassets/global/fazergroup/fazer-brainhow/brave-seminaari-13022020-handouts.pdf

1 Like

The cooperation started in 2018. I understand that the Aava cooperation has already ended. If so, why?

1 Like

TJ uses an electric car analogy in response to the question “what’s unique about this.”

If we ignore the technology and patents and FSD dreams and mass production, etc., Tesla has become big by solving practical challenges in a way that excites consumers. Electric car driving is suddenly easier, (relatively) cheaper, and more fun and sexier than burning dinosaur juice. This could be seen in a crystal ball in 2013.

Can constantly getting blood tests and reports in an app that give general instructions achieve something similar?

In my opinion, the answer is unequivocally no, sorry, this won’t become a big deal. The same crystal ball says in 2021.

If they had developed a method to get the same data with an easy and neat device like an Oura ring or something similar, then we might have a unicorn in this IPO. Or Theranos.

3 Likes

We’ll see at 4 PM if the offering is oversubscribed

My stance on this, again, has been partially the opposite: if the target audience is propeller-heads and hype-chasers looking for heartwarming innovation gadgets like Oura, the whole thing is doomed to be a curiosity. However, if such self-monitoring tools have the potential for something much less sexy, i.e., adoption in the healthcare sector, and if, for example, your family doctor who measures your blood values might recommend such a thing, then, well, there would be so much money involved that for a world-conqueror, this listing price would resemble a fly speck. This is the quarter from the business model described in Inderes’ report that interests me the most, and which I believe will also drive the development of consumer adoption. “Negotiations held, but no agreements yet” doesn’t exactly get my rigidness up, though.

The world we live in has shifted more and more towards a surveillance society in recent decades, and to put it politically neutrally, this has its benefits alongside its drawbacks. This is largely received negatively with grumbling, yet mostly accepted. This would be a logical continuation of the same change, and I consider the exponential growth of this market merely a matter of time. However, as a bear in this case, I find it suspicious that this would be a change taking off in the next few years. I believe that this change will be driven primarily by the good reasons of the rigid and conservative healthcare sector, not by innovation hype-chasers with their apps. This will surely require a million, if not a hundred, marketing budgets. In the starting blocks, I believe Nightingale has its subjective strengths here, which I do not consider absolutely massive, but which can be classified as early mover advantages. Such a financial injection will sustain the company for a long time, but it’s a long way to go far.

Tesla, in my opinion, is an insufficient comparison, as the company’s purpose and secret to success has indeed been to make its electric car a monolith of success, luxury, design, and all other earthly sexy-coolness. I do not believe that the same is a prerequisite for business in this sector, because unlike a car, the human body is not seen as an earth-polluting consumer product and status symbol (even though it is :slight_smile:).

2 Likes

Does analyzing a company like Nightgale even fit Inderes’ job description and image?

Inderes’ main message has always been to make good analyses and stock selections (=buy good companies that you have analyzed sensibly).

Now we are talking about a company that warns on page 8 of its listing prospectus: “There is no certainty that the Company will generate revenue or become profitable”.

Is this still about analyzing a company, stock investing, or more about gambling, when the company has to state something like this in its listing prospectus? I just don’t think it’s good that completely raw companies come to the stock exchange. These belong more to private equity investors and venture capitalists.

13 Likes

I was absolutely sure I’d leave the marking to others, but at the last minute, I gave in. At least there’s Swedbank’s stabilization option to help, which is practically useless. Come what may, it was an interesting offering!

1 Like